- CEO
- Ren Rong Wu
- Full Time Employees
- 718
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- Building 5, 64 Suning Avenue Nanjing JS China 210042
- IPO Date
- Jan 30, 2019
- Business
- Nanjing Well Pharmaceutical Group Co Ltd (603351:SHH), formerly Nanjing Well Pharmaceutical Co Ltd, engages principally in the research, development, manufacturing and sales of pharmaceutical auxiliary materials, synthetic lubricating base oils and pesticide additives; its core pharmaceutical excipients portfolio encompasses Polysorbate (Tween) series, Span series (fatty acid sorbitan esters), Polyethylene Glycol series, Poloxamer series and Propylene Glycol for solid, semi-solid and liquid preparations including injections, eye drops, microspheres, liposomes, suppositories, ointments and tablets, alongside active pharmaceutical ingredients (APIs), chiral intermediates, advanced intermediates, veterinary drug intermediates, probiotics, anesthetic preparations, emulsifying/solubilizing agents, microencapsulation products, solvents, suspending/viscosity increasing agents and tablet binders/fillers; the company also produces new pesticide adjuvants and animal health care products. Nanjing Well Pharmaceutical Group Co Ltd, founded in 2000 and headquartered at Block 5, R&D Zone 5, Xuzhuang Software Park, 64 Suning Avenue, Xuanwu District, Nanjing 210042, China, operates primarily in the domestic Chinese market with annual pharmaceutical excipient sales exceeding 10,000 tons and long-term supply relationships with over 1,000 pharmaceutical enterprises including Johnson & Johnson, GSK, Novartis and Bayer; subsidiaries include Nanjing Well Pharmaceutical Technology Co Ltd, a new R&D and manufacturing center in Nanjing Jiangbei New Material Science and Technology Park with 15 synthetic lines and 7 GMP packaging lines for over 20,000 tons annual output of excipients and APIs, Nanjing Well Biomaterial Co Ltd focused on agricultural surfactants, Nanjing Well Biotechnology Co Ltd, Yangzhou Weier Biotechnology Co Ltd and Nanjing Well Materials Science and Technology Research Institute Co Ltd. The company changed its name to Nanjing Well Pharmaceutical Group Co Ltd in April 2020 to reflect its expanded group structure and maintains over 100 invention patents including 11 PCT applications, with certain excipients holding CEP and US FDA DMF filings; it employs 711 people generating trailing 12-month revenue of CNY1.28 billion and net income of CNY140.29 million as of late 2024.